FOXO4-DRI

FOXO4-DRI is a synthetic D-retro-inverso peptide engineered as a laboratory tool to interfere with the FOXO4–p53 protein interaction. Its mirror-image, reverse-sequence design confers high resistance to proteolytic degradation, supporting use in extended cell-culture experiments. The compound is investigated exclusively in controlled research settings focused on cellular senescence biology. It is supplied strictly for in-vitro and laboratory research use only.

FOXO4-DRI is studied for its ability to competitively displace p53 from FOXO4 complexes that form inside senescent cells. Once released, p53 can engage canonical apoptotic transcriptional programs that are otherwise sequestered. This selective disruption is examined in cultured cell models that display the senescence-associated secretory phenotype and elevated FOXO4 expression. The peptide therefore serves as a molecular probe of p53-dependent cell-death pathways restricted to senescent populations.

Laboratory investigations of FOXO4-DRI center on cellular senescence, the irreversible growth-arrest state linked to tissue aging phenotypes in experimental systems. Researchers employ the peptide to interrogate senolytic strategies—approaches that clear non-dividing “zombie” cells—while mapping downstream effects on inflammatory signaling and tissue homeostasis markers. Additional work explores the FOXO4–p53 axis in DNA-damage and stress-response pathways using standardized cell-culture and organoid models.

Peer-reviewed studies have demonstrated that FOXO4-DRI can trigger apoptosis preferentially in senescent cells by liberating p53, while largely sparing proliferating counterparts under identical culture conditions. These observations establish the peptide as a useful chemical tool for dissecting the contribution of senescent cells to experimental models of tissue dysfunction. Results consistently highlight the importance of FOXO4 scaffolding in maintaining senescent-cell viability.

FOXO4-DRI should be stored desiccated at low temperature and reconstituted in sterile aqueous buffers immediately before use in cell-based assays. Standard peptide-handling precautions, including avoidance of repeated freeze–thaw cycles and protection from prolonged light exposure, help preserve activity. All work must remain confined to qualified laboratory environments; the material is not intended for any non-research purpose.